Laurent Levy and Tanguy Lim-Seiwert, MD, on the Potential of NBTXR3 to Treat Patients With Head and Neck Cancers

Video

CancerNetwork® spoke with the CEO of Nanobiotix and an assistant professor of Oncology at John Hopkins Medicine to learn more regarding the potential of the radio enhancer NBTXR3.

CancerNetwork® spoke with Laurent Levy, CEO of Nanobiotix, and Tanguy Lim-Seiwert, MD, of John Hopkins Medicine, to discuss the potential of NBTXR3, a radio enhancer designed to destroy tumors through physical cell death when activated by radiotherapy.

“We started this company with the idea that, instead of using chemistry or biology to treat cancer, maybe we should try another path,” explained Levy. “That’s why we decided to use physics, and we decided to bring physics into the cell to make sure we can have a treatment that could benefit millions of patients. That’s what led us to invent NBTXR3.”

The agent provided positive results in a number of trials, including data from a phase 3 soft tissue sarcoma trial in Europe, investigating NBTXR3 activated by current standard of care radiation therapy.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content
FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

April 12th 2024
Article

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

Radiation Therapy Plus Chemo Yielded Increased Efficacy in HPV+ Oropharynx Cancer

March 4th 2024
Article

The use of postoperative adjuvant radiation therapy led to less weight loss in patients with HPV-positive oropharynx cancer, according to Wade L. Thorstad, MD.

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.

Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC

March 1st 2024
Article

Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

FDA Clears Oral Stent Solution for Radiotherapy in Head and Neck Cancer

January 22nd 2024
Article

The FDA grants clearance to an oral immobilization stent designed to redirect radiation to the target tumor area for patients with head and neck cancer.

After observing a prevalence of thyroid cancer among transgender female patients through clinical observation, a study was prompted by clinicians in order to determine if this is an issue in a larger population.

Thyroid Cancer Rates Are Higher Among Transgender Female Veterans

October 29th 2023
Article

Study shows a high prevalence of thyroid cancer in transgender female patients.